Tech Company Financing Transactions
AveXis Funding Round
AveXis closed a $10 million funding round on 1/10/2015. Backers included Deerfield Capital and Roche Venture Fund.
Transaction Overview
Company Name
Announced On
1/10/2015
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
Deerfield Capital (Lead Investor) (Jonathan Leff)
Roche Venture Fund (Lead Investor) (Carole Nuechterlein)
Proceeds Purpose
Proceeds from the financing will be used to further the development of the Company's gene therapy product, chariSMATM, including additional support for the current Phase I clinical trial in SMA Type 1 infants.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2275 Half Day Rd. 200
Bannockburn, IL 60015
USA
Bannockburn, IL 60015
USA
Phone
Website
Email Address
Overview
AveXis is focused on developing gene therapy for patients with rare and life-threatening neurological genetic diseases, like spinal muscular atrophy (SMA).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean Nolan
Chief Financial Officer
Phillip Donenberg
Chief Medical Officer
Sukumar Nagendran
Chief Scientific Officer
Allan Kaspar
VP - Bus. Development
Rick Modi
VP - Bus. Development
RA Session
VP - General Counsel
Michael Johannesen
VP - Human Resources
Lori Smith
VP - Manufacturing
Andrew Knudten
VP - Regulatory Affairs
James L'Italien
Browse more venture capital transactions:
Prev: 1/10/2015: Okanjo venture capital transaction
Next: 1/10/2015: AlayaCare venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs